{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:54:17Z","timestamp":1776862457323,"version":"3.51.2"},"reference-count":114,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1097\/md.0000000000008045","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T16:39:49Z","timestamp":1508344789000},"page":"e8045","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis"],"prefix":"10.1097","volume":"96","author":[{"given":"Alejandro","family":"G\u00f3mez-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Est\u00edbaliz","family":"Loza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Piedad","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M. Garc\u00eda Ruiz de","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Herreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Cordero-Coma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-31-20210226","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1076\/ocii.10.4.263.15592","article-title":"Uveitis: a global perspective","volume":"10","author":"Chang","year":"2002","journal-title":"Ocul Immunol Inflamm"},{"key":"R2-31-20210226","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0002-9394(14)74235-7","article-title":"International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease","volume":"103","author":"Bloch-Michel","year":"1987","journal-title":"Am J Ophthalmol"},{"key":"R3-31-20210226","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.survophthal.2005.04.003","article-title":"Acute anterior uveitis and HLA-B27","volume":"50","author":"Chang","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"R4-31-20210226","first-page":"487","article-title":"Uveitis. Best practice and research","volume":"20","author":"Munoz-Fernandez","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R5-31-20210226","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0049-0172(95)80011-5","article-title":"Acute anterior uveitis: clinical and experimental aspects","volume":"24","author":"Careless","year":"1995","journal-title":"Semin Arthritis Rheum"},{"key":"R6-31-20210226","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2010.04.031","article-title":"Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis","volume":"150","author":"Loh","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R7-31-20210226","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jfo.2010.07.002","article-title":"Refractory anterior uveitis","volume":"34","author":"Labalette","year":"2011","journal-title":"J Fr Ophtalmol"},{"key":"R8-31-20210226","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0161-6420(98)99033-9","article-title":"Outcomes in anterior uveitis associated with the HLA-B27 haplotype","volume":"105","author":"Power","year":"1998","journal-title":"Ophthalmology"},{"key":"R9-31-20210226","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/jop.2008.0087","article-title":"Complications and safety profile of posterior subtenon injection of triamcinolone acetonide","volume":"25","author":"Byun","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"R10-31-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2015.07.001","article-title":"The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management","volume":"61","author":"Foster","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"R11-31-20210226","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/eye.2000.84","article-title":"Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis","volume":"14","author":"Benitez-Del-Castillo","year":"2000","journal-title":"Eye"},{"key":"R12-31-20210226","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/eye.2008.198","article-title":"Methotrexate: an option for preventing the recurrence of acute anterior uveitis","volume":"23","author":"Munoz-Fernandez","year":"2009","journal-title":"Eye"},{"key":"R13-31-20210226","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R14-31-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R16-31-20210226","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/aos.12127","article-title":"Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids","volume":"91","author":"Abu El-Asrar","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R17-31-20210226","first-page":"S84","article-title":"Cyclosporine for Behcet's uveitis: is it associated with an increased risk of neurological involvement?","volume":"26","author":"Akman-Demir","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R18-31-20210226","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/09273948.2013.779727","article-title":"Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab","volume":"21","author":"Al Rashidi","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"R19-31-20210226","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"R20-31-20210226","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s00417-003-0789-3","article-title":"Outcomes of early and late immunomodulatory treatment in patients with HLA-B27-associated chronic uveitis","volume":"241","author":"Androudi","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol [Albrecht von Graefes Archiv f\u00fcr klinische und experimentelle Ophthalmologie"},{"key":"R21-31-20210226","first-page":"69","article-title":"The efficacy and safety of adalimumab in ocular inflammatory disease","volume":"5","author":"Arcinue","year":"2015","journal-title":"Orphan Drugs Res Rev"},{"key":"R22-31-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ajo.2014.10.013","article-title":"Uveitis in Behcet disease in a tertiary center over 25 years: the KKESH Uveitis Survey Study Group","volume":"159","author":"Arevalo","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R23-31-20210226","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00417-014-2856-3","article-title":"Anti-interferon alpha antibodies and autoantibodies in patients with Behcet's disease uveitis treated with recombinant human interferon alpha-2a","volume":"253","author":"Aydinoglu-Candan","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol [Albrecht von Graefes Archiv f\u00fcr klinische und experimentelle Ophthalmologie"},{"key":"R24-31-20210226","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4321\/S1130-01082012000900004","article-title":"Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease","volume":"104","author":"Barreiro-de-Acosta","year":"2012","journal-title":"Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva"},{"key":"R25-31-20210226","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"R26-31-20210226","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00417-014-2696-1","article-title":"Five-year outcome in immune-mediated scleritis","volume":"252","author":"Bernauer","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol [Albrecht von Graefes Archiv f\u00fcr klinische und experimentelle Ophthalmologie"},{"key":"R27-31-20210226","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s100670050027","article-title":"Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study","volume":"19","author":"Biasi","year":"2000","journal-title":"Clin Rheumatol"},{"key":"R28-31-20210226","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R29-31-20210226","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"key":"R30-31-20210226","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients","volume":"53","author":"Calvo-Rio","year":"2014","journal-title":"Rheumatology"},{"key":"R31-31-20210226","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/112067210901900117","article-title":"Induction of durable remission in ocular inflammatory diseases","volume":"19","author":"Cervantes-Castaneda","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R32-31-20210226","first-page":"487","article-title":"Intraocular penetration of cyclosporin A in uveitis","volume":"64","author":"Chipont","year":"1993","journal-title":"Archivos de la Sociedad Espanola de Oftalmologia"},{"key":"R33-31-20210226","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/09273948.2012.723107","article-title":"Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis","volume":"21","author":"Cordero-Coma","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"R34-31-20210226","doi-asserted-by":"crossref","first-page":"717598","DOI":"10.1155\/2014\/717598","article-title":"Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience","volume":"2014","author":"Cordero-Coma","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R35-31-20210226","first-page":"277","article-title":"Treatment of non infectious ocular inflammatory disease with low doses of cyclosporin A","volume":"127","author":"Cuchacovich","year":"1999","journal-title":"Tratamiento con dosis bajas de ciclosporina A en pacientes con enfermedad ocular inflamatoria de etiologia no infecciosa"},{"key":"R36-31-20210226","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/0-306-48382-3_118","article-title":"High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results","volume":"528","author":"Davatchi","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"R37-31-20210226","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10792-015-0124-0","article-title":"Biologic therapy for refractory scleritis: a new treatment perspective","volume":"35","author":"de Fidelix","year":"2015","journal-title":"Int Ophthalmol"},{"key":"R38-31-20210226","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(99)05131-4","article-title":"Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behcet's disease: a randomised trial","volume":"355","author":"Demiroglu","year":"2000","journal-title":"Lancet"},{"key":"R39-31-20210226","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R40-31-20210226","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Diaz-Llopis","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"R41-31-20210226","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"Diaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"R42-31-20210226","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"4","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"R43-31-20210226","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","article-title":"Adalimumab for ocular inflammation","volume":"25","author":"Durrani","year":"2016","journal-title":"Ocular Immunol Inflamm"},{"key":"R44-31-20210226","first-page":"75","article-title":"Comparative study of the treatment of autoimmune uveitis with prednisone and with cyclophosphamide and azathioprine","volume":"48","author":"Flores","year":"2001","journal-title":"Estudio comparativo entre el tratamiento de la uveitis autoinmune con prednisona y con ciclofosfamida y azatioprina"},{"key":"R45-31-20210226","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"4","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R46-31-20210226","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0021-5155(99)00025-8","article-title":"Ciclosporin microemulsion preconcentrate treatment of patients with Behcet's disease","volume":"43","author":"Fujino","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"R47-31-20210226","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"key":"R48-31-20210226","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"R49-31-20210226","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"key":"R50-31-20210226","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R51-31-20210226","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","article-title":"Interferon alpha-2a therapy in patients with refractory Beh\u00e7et uveitis","volume":"25","author":"Hasanreisoglu","year":"2016","journal-title":"Ocular Immunol Inflamm"},{"key":"R52-31-20210226","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis","volume":"114","author":"Hogan","year":"2007","journal-title":"Ophthalmology"},{"key":"R53-31-20210226","first-page":"ra72","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"52","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"R54-31-20210226","first-page":"S58","article-title":"Adalimumab for treatment of severe Behcet's uveitis: a retrospective long-term follow-up study","volume":"32","author":"Interlandi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R55-31-20210226","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1097\/01.ASN.0000034945.61533.26","article-title":"Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study","volume":"13","author":"Isnard Bagnis","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R56-31-20210226","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ophtha.2013.11.032","article-title":"Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis","volume":"121","author":"Joshi","year":"2014","journal-title":"Ophthalmology"},{"key":"R57-31-20210226","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/09273948.2015.1125508","article-title":"Multiple sclerosis-related uveitis: Does MS treatment affect uveitis course?","volume":"25","author":"Jouve","year":"2016","journal-title":"Ocular Immunol Inflamm"},{"key":"R58-31-20210226","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1076\/ocii.11.2.131.15919","article-title":"Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis","volume":"11","author":"Kaplan-Messas","year":"2003","journal-title":"Ocular Immunol Inflamm"},{"key":"R59-31-20210226","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s10067-016-3318-6","article-title":"Long-term efficacy and safety of interferon \u03b1-2a therapy in severe refractory ophthalmic Behcet's disease","volume":"35","author":"Kavandi","year":"2003","journal-title":"Clin Rheumatol"},{"key":"R60-31-20210226","first-page":"896","article-title":"Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a","volume":"35","author":"Krause","year":"2008","journal-title":"J Rheumatol"},{"key":"R61-31-20210226","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"key":"R62-31-20210226","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(99)90078-7","article-title":"Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease","volume":"106","author":"Larkin","year":"1999","journal-title":"Ophthalmology"},{"key":"R63-31-20210226","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1046\/j.1442-9071.2003.00704.x","article-title":"Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation","volume":"31","author":"Lau","year":"2003","journal-title":"Clin Exp Ophthalmol"},{"key":"R64-31-20210226","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3341\/kjo.2012.26.1.21","article-title":"Clinical outcomes of cyclosporine treatment for noninfectious uveitis","volume":"26","author":"Lee","year":"2012","journal-title":"Korean J Ophthalmol"},{"key":"R65-31-20210226","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s10067-015-2989-8","article-title":"Anti-TNF\u03b1 agents and methotrexate in spondyloarthritis related uveitis in a Chinese population","volume":"34","author":"Lian","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R66-31-20210226","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/09273948.2011.633205","article-title":"Infliximab and adalimumab for uveitis","volume":"20","author":"Martel","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"R67-31-20210226","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et's syndrome: a single masked trial [Internet]","volume":"4","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"R68-31-20210226","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(02)01932-2","article-title":"Treatment of ocular inflammatory disorders with daclizumab","volume":"110","author":"Papaliodis","year":"2003","journal-title":"Ophthalmology"},{"key":"R69-31-20210226","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-014-0017-9","article-title":"Autoimmune uveitis: a retrospective analysis of 104 patients from a tertiary reference center","volume":"4","author":"Prete","year":"2014","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R70-31-20210226","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","article-title":"Anti-TNF-alpha therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients","volume":"45","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R71-31-20210226","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R72-31-20210226","first-page":"CD001084","article-title":"Pharmacotherapy for Behcet's syndrome","volume":"2","author":"Saenz","year":"2000","journal-title":"Cochrane Database of Syst Rev"},{"key":"R73-31-20210226","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2011.07.043","article-title":"Scleritis therapy","volume":"119","author":"Sainz de la Maza","year":"2012","journal-title":"Ophthalmology"},{"key":"R74-31-20210226","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/bjophthalmol-2015-306902","article-title":"Scleritis associated with relapsing polychondritis","volume":"100","author":"Sainz de la Maza","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R75-31-20210226","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bjophthalmol-2012-302515","article-title":"Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis","volume":"97","author":"Sakai","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R76-31-20210226","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/09273948.2013.812222","article-title":"Recurrence of uveitis after discontinuation of infliximab","volume":"22","author":"Shakoor","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"R77-31-20210226","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R78-31-20210226","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2015.05.006","article-title":"Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review","volume":"45","author":"Simonini","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R79-31-20210226","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R80-31-20210226","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments","volume":"117","author":"Sobaci","year":"2010","journal-title":"Ophthalmology"},{"key":"R81-31-20210226","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","article-title":"Infliximab therapy for the treatment of refractory ocular inflammatory disease","volume":"125","author":"Sobrin","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R82-31-20210226","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ophtha.2007.12.011","article-title":"Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis","volume":"115","author":"Sobrin","year":"2008","journal-title":"Ophthalmology"},{"key":"R83-31-20210226","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R84-31-20210226","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bjophthalmol-2012-302292","article-title":"Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial","volume":"97","author":"Suhler","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R85-31-20210226","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology"},{"key":"R86-31-20210226","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin: a therapy in severe uveitis of Behcet's disease","volume":"76","author":"Sullu","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"key":"R87-31-20210226","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/09273948.2012.665124","article-title":"Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behcet's disease","volume":"20","author":"Takeuchi","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"R88-31-20210226","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/imt.12.134","article-title":"A systematic review of biologics for the treatment of noninfectious uveitis","volume":"5","author":"Takeuchi","year":"2013","journal-title":"Immunotherapy"},{"key":"R89-31-20210226","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet's disease: a multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"key":"R90-31-20210226","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Behcet uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol [Albrecht von Graefes Archiv f\u00fcr klinische und experimentelle Ophthalmologie"},{"key":"R91-31-20210226","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","article-title":"Safety and efficacy of gevokizumab in patients with Beh\u00e7et's disease uveitis: results of an exploratory phase 2 study","volume":"25","author":"Tugal-Tutkun","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"R92-31-20210226","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Behcet's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"R93-31-20210226","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R94-31-20210226","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0161-6420(96)30683-0","article-title":"Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis","volume":"103","author":"Vitale","year":"1996","journal-title":"Ophthalmology"},{"key":"R95-31-20210226","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2012.08.005","article-title":"Visual outcome, treatment results, and prognostic factors in patients with scleritis","volume":"120","author":"Wieringa","year":"2013","journal-title":"Ophthalmology"},{"key":"R96-31-20210226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12891-015-0489-2","article-title":"Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis","volume":"16","author":"Wu","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"R97-31-20210226","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome [Internet]","volume":"5","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"R98-31-20210226","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1590\/S0004-27492010000100007","article-title":"Chlorambucil and cyclosporine A in Brazilian patients with Behcet's disease uveitis: a retrospective study","volume":"73","author":"Zaghetto","year":"2010","journal-title":"Arq Bras Oftalmol"},{"key":"R99-31-20210226","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00005-016-0402-1","article-title":"High efficacy of methotrexate in patients with recurrent idiopathic acute anterior uveitis: a prospective study","volume":"65","author":"Bachta","year":"2016","journal-title":"Arch Immunol Ther Exp"},{"key":"R100-31-20210226","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R101-31-20210226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","article-title":"A three-centre experience with adalimumab for the treatment of non-infectious uveitis [Internet]","volume":"2","author":"Dobner","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R102-31-20210226","first-page":"81","article-title":"Prevention of acute anterior uveitis associated with spondylarthropathy induced by salazosulfapyridine","volume":"60","author":"Dougados","year":"1993","journal-title":"Rev Rhum Ed Fr"},{"key":"R103-31-20210226","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"R104-31-20210226","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Kacmaz","year":"2010","journal-title":"Ophthalmology"},{"key":"R105-31-20210226","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/bjo.53.5.327","article-title":"Azathioprine in active chronic iridocyclitis. A double-blind controlled trial [Internet]","volume":"5","author":"Mathews","year":"1969","journal-title":"Br J Ophthalmol"},{"key":"R106-31-20210226","first-page":"1277","article-title":"Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period","volume":"30","author":"Munoz-Fernandez","year":"2003","journal-title":"J Rheumatol"},{"key":"R107-31-20210226","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R108-31-20210226","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R109-31-20210226","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0161-6420(01)00576-0","article-title":"Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients","volume":"108","author":"Samson","year":"2001","journal-title":"Ophthalmology"},{"key":"R110-31-20210226","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10792-016-0239-y","article-title":"Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis","volume":"37","author":"Yazgan","year":"2016","journal-title":"Int Ophthalmol"},{"key":"R111-31-20210226","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jbspin.2016.02.028","article-title":"Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers","volume":"84","author":"de La Forest Divonne","year":"2016","journal-title":"Joint Bone Spine"},{"key":"R112-31-20210226","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10384-012-0202-z","article-title":"Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis","volume":"57","author":"Matsuda","year":"2013","journal-title":"Jpn J Ophthalmol"},{"key":"R113-31-20210226","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","article-title":"Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis","volume":"109","author":"El-Shabrawi","year":"2002","journal-title":"Ophthalmology"},{"key":"R114-31-20210226","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti-IL6-R Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to anti-TNF therapy. A multicenter study of 25 patients","volume":"69","author":"Calvo-Rio","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R115-31-20210226","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s10067-016-3426-3","article-title":"Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art","volume":"35","author":"Fabiani","year":"2016","journal-title":"Clin Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:33:07Z","timestamp":1620959587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201710200-00031"}},"subtitle":["A systematic literature review"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":114,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008045","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}